BG108400A - Лечение на adhd - Google Patents

Лечение на adhd Download PDF

Info

Publication number: BG108400A
Authority: BG; Bulgaria
Prior art keywords: indole; dihydro; acetyl; chloro; ethyl
Prior art date: 2001-05-09

Application number

BG108400A

Other languages

Bulgarian (bg)

English (en)

Inventor

Klaus Hertel

Jorn Arnt

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-09

Filing date

2003-12-01

Publication date

2004-11-30

2003-12-01 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2004-11-30 Publication of BG108400A publication Critical patent/BG108400A/bg

Links

208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 21
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 21
150000003839 salts Chemical class 0.000 claims abstract description 12
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 4
238000002360 preparation method Methods 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
208000013403 hyperactivity Diseases 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
230000006735 deficit Effects 0.000 claims description 5
YVIUVYJJSZFGCX-LJQANCHMSA-N 1-[(3s)-3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)C[C@H]1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 YVIUVYJJSZFGCX-LJQANCHMSA-N 0.000 claims description 2
-1 1-acetyl-2,3-dihydro-1 H -indol-3-yl Chemical group 0.000 claims description 2
238000000034 method Methods 0.000 claims 3
TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 1
235000014676 Phragmites communis Nutrition 0.000 claims 1
YVIUVYJJSZFGCX-UHFFFAOYSA-N 1-[3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 YVIUVYJJSZFGCX-UHFFFAOYSA-N 0.000 abstract description 6
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000003368 psychostimulant agent Substances 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
239000000654 additive Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
208000020016 psychiatric disease Diseases 0.000 description 4
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 3
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960001344 methylphenidate Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
230000000862 serotonergic effect Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000030990 Impulse-control disease Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
230000008236 biological pathway Effects 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
229960000632 dexamfetamine Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
125000003392 indanyl group Chemical class C1(CCC2=CC=CC=C12)* 0.000 description 1
LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000012155 injection solvent Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000001730 monoaminergic effect Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229950002315 quipazine Drugs 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000015961 tonic Nutrition 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
229960000716 tonics Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Recrystallisation Techniques (AREA)
Indole Compounds (AREA)

BG108400A 2001-05-09 2003-12-01 Лечение на adhd BG108400A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200100732		2001-05-09

Publications (1)

Publication Number	Publication Date
BG108400A true BG108400A (bg)	2004-11-30

Family

ID=8160484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108400A BG108400A (bg)	2001-05-09	2003-12-01	Лечение на adhd

Country Status (23)

Country	Link
US (1)	US7294638B2 (is)
EP (1)	EP1387682A1 (is)
JP (1)	JP2004528361A (is)
KR (1)	KR20040007544A (is)
CN (1)	CN1507351A (is)
AR (1)	AR033287A1 (is)
BG (1)	BG108400A (is)
BR (1)	BR0209443A (is)
CA (1)	CA2446652A1 (is)
CO (1)	CO5540378A2 (is)
CZ (1)	CZ20033197A3 (is)
EA (1)	EA200301221A1 (is)
HR (1)	HRP20030852A2 (is)
HU (1)	HUP0400075A2 (is)
IL (1)	IL158413A0 (is)
IS (1)	IS6992A (is)
MX (1)	MXPA03010136A (is)
NO (1)	NO20034972L (is)
NZ (1)	NZ528896A (is)
PL (1)	PL367778A1 (is)
SK (1)	SK15002003A3 (is)
WO (1)	WO2002089797A1 (is)
ZA (1)	ZA200307955B (is)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003236207A1 (en) *	2002-05-31	2003-12-19	H. Lundbeck A/S	The hydrochloride of (s)-(+)-3-(1-(2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1h-indole
EP1812390A2 (en) *	2004-10-22	2007-08-01	Mark Froimowitz	Methylphenidate analogs and methods of use thereof
WO2009136410A2 (en) *	2008-04-19	2009-11-12	Nisarga Biotech Pvt. Ltd.	Herbal composition for reducing add/adhd and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521197A (en) *	1994-12-01	1996-05-28	Eli Lilly And Company	3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
ZA9711376B (en) *	1996-12-20	1998-07-21	Lundbeck & Co As H	Indole or dihydroindole derivatives
AU2002230665A1 (en) *	2000-12-06	2002-06-18	Sepracor, Inc.	4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands

2002
- 2002-04-29 AR ARP020101569A patent/AR033287A1/es not_active Application Discontinuation
- 2002-05-07 CN CNA028095790A patent/CN1507351A/zh active Pending
- 2002-05-07 JP JP2002586932A patent/JP2004528361A/ja active Pending
- 2002-05-07 SK SK1500-2003A patent/SK15002003A3/sk unknown
- 2002-05-07 EA EA200301221A patent/EA200301221A1/ru unknown
- 2002-05-07 CZ CZ20033197A patent/CZ20033197A3/cs unknown
- 2002-05-07 KR KR10-2003-7014554A patent/KR20040007544A/ko not_active Withdrawn
- 2002-05-07 MX MXPA03010136A patent/MXPA03010136A/es unknown
- 2002-05-07 PL PL02367778A patent/PL367778A1/xx not_active Application Discontinuation
- 2002-05-07 WO PCT/DK2002/000298 patent/WO2002089797A1/en not_active Ceased
- 2002-05-07 IL IL15841302A patent/IL158413A0/xx unknown
- 2002-05-07 HR HR20030852A patent/HRP20030852A2/hr not_active Application Discontinuation
- 2002-05-07 NZ NZ52889602A patent/NZ528896A/xx unknown
- 2002-05-07 BR BR0209443-6A patent/BR0209443A/pt not_active IP Right Cessation
- 2002-05-07 US US10/477,382 patent/US7294638B2/en not_active Expired - Lifetime
- 2002-05-07 HU HU0400075A patent/HUP0400075A2/hu unknown
- 2002-05-07 EP EP02724146A patent/EP1387682A1/en not_active Withdrawn
- 2002-05-07 CA CA002446652A patent/CA2446652A1/en not_active Abandoned
2003
- 2003-10-13 ZA ZA200307955A patent/ZA200307955B/en unknown
- 2003-10-13 IS IS6992A patent/IS6992A/is unknown
- 2003-11-07 NO NO20034972A patent/NO20034972L/no not_active Application Discontinuation
- 2003-11-27 CO CO03104809A patent/CO5540378A2/es not_active Application Discontinuation
- 2003-12-01 BG BG108400A patent/BG108400A/bg unknown

Also Published As

Publication number	Publication date
WO2002089797A8 (en)	2004-03-25
IS6992A (is)	2003-10-13
US20040152737A1 (en)	2004-08-05
ZA200307955B (en)	2004-10-13
JP2004528361A (ja)	2004-09-16
CA2446652A1 (en)	2002-11-14
US7294638B2 (en)	2007-11-13
HRP20030852A2 (en)	2005-06-30
AR033287A1 (es)	2003-12-10
IL158413A0 (en)	2004-05-12
HUP0400075A2 (hu)	2004-04-28
CN1507351A (zh)	2004-06-23
CZ20033197A3 (en)	2004-06-16
PL367778A1 (en)	2005-03-07
NO20034972D0 (no)	2003-11-07
KR20040007544A (ko)	2004-01-24
CO5540378A2 (es)	2005-07-29
SK15002003A3 (sk)	2004-05-04
WO2002089797A1 (en)	2002-11-14
MXPA03010136A (es)	2004-03-10
BR0209443A (pt)	2004-08-03
NO20034972L (no)	2003-11-07
NZ528896A (en)	2004-12-24
EP1387682A1 (en)	2004-02-11
EA200301221A1 (ru)	2004-04-29

Publication	Publication Date	Title
CN1087937C (zh)	2002-07-24	抑制阿尔茨海默症的药物
CN1084618C (zh)	2002-05-15	5－羟色胺拮抗剂的新应用
JP2002226401A (ja)	2002-08-14	うつ病の併用療法
JPH02290872A (ja)	1990-11-30	５―クロロ―１―（４―フルオロフェニル）　―３―（１―（２―　（２―イミダゾリジノン―１―イル）エチル）　―４―ピペリジル）―１ｈ―インドールまたはその薬学的に容認できる酸付加塩を使用する方法
JP2005520780A (ja)	2005-07-14	Ｄ−ｔｈｒｅｏメチルフェニデートを用いる認識および閉経期の障害の治療方法
KR20200020726A (ko)	2020-02-26	외상 후 스트레스 장애의 치료를 위한 제제
US9737524B2 (en)	2017-08-22	Prophylactic and/or therapeutic agent for mild cognitive impairment
CN1088359C (zh)	2002-07-31	治疗脑血管障碍伴随的精神障碍的药物
JP2004507503A (ja)	2004-03-11	記憶を増強するためのトレオ−メチルフェニデートの使用
Fischhof et al.	1992	Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID)
JP2018203774A (ja)	2018-12-27	精神障害の治療における使用のためのイロペリドン代謝物
US20030176488A1 (en)	2003-09-18	Method for treating depression
BG108400A (bg)	2004-11-30	Лечение на adhd
KR20190006515A (ko)	2019-01-18	App 의 정상 가공을 촉진하는 화합물
CN1216598C (zh)	2005-08-31	药物用途
JP2024523485A (ja)	2024-06-28	少なくとも１種類のセロトニン再取り込み阻害剤及び少なくとも１種の塩化カリウム共輸送体２型の刺激剤を含む組み合せ、並びにその医学的使用
JPS5823618A (ja)	1983-02-12	精神分裂症を治療する組成物
HK1067041A (en)	2005-04-01	Treatment of adhd
CN1447809A (zh)	2003-10-08	神经变性疾病的预防和治疗药物
AU2002254875A1 (en)	2002-11-18	Treatment of ADHD
JPH0827029A (ja)	1996-01-30	５ｈｔ１作動薬の新規医薬用途
JP2007533699A (ja)	2007-11-22	医薬